Not Yet RecruitingNot Applicable

Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

China20 participantsStarted 2026-03-16

Plain-language summary

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age 18-80 years, regardless of gender;
✓. Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
✓. Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
✓. Patient is intolerant to or refuses surgical resection;
✓. ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.

✕. Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
✕. Massive or diffuse hepatocellular carcinoma;
✕. Presence of vascular tumor thrombus or invasion of adjacent organs;
✕. History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
✕. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;
✕. Refractory massive ascites, cachexia;
✕. Active infection, especially inflammatory conditions of the biliary system;
✕

Ablation efficacy rate at 1 month postoperatively

Timeframe: 1 month after ablation

NCT IDNCT07459309

SponsorFudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

wentao li

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age 18-80 years, regardless of gender;
✓. Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
✓. Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
✓. Patient is intolerant to or refuses surgical resection;
✓. ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.

✕. Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
✕. Massive or diffuse hepatocellular carcinoma;
✕. Presence of vascular tumor thrombus or invasion of adjacent organs;
✕. History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
✕. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;
✕. Refractory massive ascites, cachexia;
✕. Active infection, especially inflammatory conditions of the biliary system;
✕